Lilly leads big pharma in new Alzheimer's paradigm
This article was originally published in Scrip
Executive Summary
Lilly is the leading big pharma player in a new paradigm of Alzheimer's disease drug development, according to the latest analysis by Citeline. The firm is conducting four clinical trials (from Phase I to Phase III) in earlier stage patients, making it the top trial sponsor in the emerging concept of targeting treatment at patients with mild cognitive impairment with a view to preventing progression to AD.